ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boeree, M.
Right arrow Articles by Kleibeuker, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boeree, M.
Right arrow Articles by Kleibeuker, J.
Eur Respir J 1998; 11: 1070-1074
Copyright © ERS Journals Ltd 1998

Clinical Trial

No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux

MJ Boeree, FT Peters, DS Postma, and JH Kleibeuker

Acid gastro-oesophageal reflux may aggravate respiratory symptoms in patients with asthma and chronic obstructive pulmonary disease (COPD) by increasing airway hyperresponsiveness through vagally-mediated pathways. We wanted to determine whether elimination of acid reflux could improve symptoms in such patients. In a randomized, double-blind, placebo-controlled study, 36 allergic and nonallergic subjects (17 males and 19 females, mean age 52 yrs), with airway obstruction and severe airway hyperresponsiveness despite maintenance treatment with an inhaled corticosteroid and with increased acid gastro-oesophageal reflux, were treated either with omeprazole, 40 mg b.i.d., or placebo for 3 months. Primary endpoints were: airway hyperresponsiveness, as determined by the provocative concentration of methacholine producing a 20% fall in forced expiratory volume in one second (PC20); and airway obstruction. Secondary endpoints were: peak expiratory flow variability; reversibility to inhaled ipratropium bromide as a parameter of vagal activity; asthma symptoms scores; and medication used. Reflux was measured by 24 h ambulatory intraoesophageal pH measurement. Omeprazole, 40 mg b.i.d., for 3 months had no beneficial effect on any of the pulmonary parameters, despite its profound effect on acid reflux and improvement of reflux symptoms scores, compared to placebo. The results of this study do not support a role for intensive antireflux therapy to improve pulmonary symptoms and function in patients with asthma and chronic obstructive pulmonary disease, who have severe airway hyperresponsiveness despite maintenance treatment with inhaled corticosteroids.


This article has been cited by other articles:


Home page
 EDUCATION AND PRACTICEHome page
M P Tighe, M Cullen, and R M Beattie
How to use: a pH study
Arch. Dis. Child. Ed. Pract., February 1, 2009; 94(1): 18 - 23.
[Full Text] [PDF]

Home page
 Br. J. Sports. Med.Home page
M Ferrari, F Bonella, L Benini, P Ferrari, F De Iorio, R Testi, and V Lo Cascio
Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
Br. J. Sports Med., October 1, 2008; 42(10): 845 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. O. Kiljander, S. M. Harding, S. K. Field, M. R. Stein, H. S. Nelson, J. Ekelund, M. Illueca, O. Beckman, and M. B. Sostek
Effects of Esomeprazole 40 mg Twice Daily on Asthma: A Randomized Placebo-controlled Trial
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1091 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 Fam PractHome page
A P. S Hungin, A. S Raghunath, and I. Wiklund
Beyond heartburn: a systematic review of the extra-oesophageal spectrum of reflux-induced disease
Fam. Pract., December 1, 2005; 22(6): 591 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
K Stordal, G B Johannesdottir, B S Bentsen, P K Knudsen, K C L Carlsen, O Closs, M Handeland, H K Holm, and L Sandvik
Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease
Arch. Dis. Child., September 1, 2005; 90(9): 956 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J L Mathew, M Singh, and S K Mittal
Gastro-oesophageal reflux and bronchial asthma: current status and future directions
Postgrad. Med. J., December 1, 2004; 80(950): 701 - 705.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. O. Kiljander and J. O. Laitinen
The Prevalence of Gastroesophageal Reflux Disease in Adult Asthmatics
Chest, November 1, 2004; 126(5): 1490 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S K FIELD, L R SUTHERLAND, and P GIBSON
Gastro-oesophageal reflux and asthma
Thorax, November 1, 2001; 56(11): 898 - 898.
[Full Text] [PDF]

Home page
 ThoraxHome page
J L Coughlan, P G Gibson, and R L Henry
Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review
Thorax, March 1, 2001; 56(3): 198 - 204.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. M. HARDING, M. R. GUZZO, and J. E. RICHTER
The Prevalence of Gastroesophageal Reflux in Asthma Patients without Reflux Symptoms
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 34 - 39.
[Abstract] [Full Text]

Home page
 ChestHome page
T. O. Kiljander, E.-R. M. Salomaa, E. K. Hietanen, and E. O. Terho
Gastroesophageal Reflux in Asthmatics: A Double-Blind, Placebo-Controlled Crossover Study With Omeprazole
Chest, November 1, 1999; 116(5): 1257 - 1264.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.